Akram Muhammad Noman, Khokhar Muhammad Imran, Abbas Mateen, Waqas Muhammad Khurram, Mustafa Mian Waqar, Alamri Abdulhakeem S, Alhomrani Majid, Alsanie Walaa F, Usman Muhammad
Int J Clin Pharmacol Ther. 2024 Jun;62(6):259-266. doi: 10.5414/CP204534.
Vancomycin is being used for the treatment of a variety of infections caused by methicillin resistant and methicillin susceptible . Therapeutic drug monitoring (TDM) is highly recommended for ensuring the safe and effective therapy with vancomycin. A reliable and cost-effective bioanalytical method is required for TDM as well as pharmacokinetic studies of vancomycin.
A selective, sensitive, and cost effective HPLC method was developed and validated for quantification of vancomycin concentrations in human plasma. The mobile phase was a mixture of buffer (50 mM ammonium dihydrogen phosphate, pH 2.4) and acetonitrile 88 : 12 v/v. The separation was carried on C18 column (125 × 4.6 mm, particle size 5 µm) with isocratic flow rate of 0.370 mL/min at room temperature with UV detection at 215 nm. The method was validated for sensitivity, accuracy, and precision as well as stability of vancomycin in human plasma by following European Medicine Agency (EMA) guideline. Therapeutic drug monitoring of vancomycin was performed by quantifying the trough concentrations of vancomycin in 65 human plasma samples after administration of therapeutically relevant dose.
The developed method was sensitive enough to quantify vancomycin concentrations as low as 0.25 mg/L in human plasma. Moreover, the method was proved accurate and precise in terms of quantifying the unknown concentration of vancomycin. The evaluation of short-term, long-term, and freeze-thaw stability proved the stability of vancomycin in human plasma. The TDM of vancomycin by using this method showed that 39 (60%) samples were within the target trough concentration range (TTCR), i.e. 10 - 20 mg/L, while 23 samples (35.4%) were below the TTCR, and 3 samples (4.6%) were above this range.
The developed method is sensitive and cost effective for quantification of vancomycin in human plasma. The results of sample analysis shows that the developed method can be used reliably for TDM of vancomycin.
万古霉素正用于治疗由耐甲氧西林和甲氧西林敏感菌引起的多种感染。强烈推荐进行治疗药物监测(TDM)以确保万古霉素治疗的安全有效。TDM以及万古霉素的药代动力学研究都需要一种可靠且经济高效的生物分析方法。
开发并验证了一种选择性好、灵敏度高且经济高效的HPLC方法,用于定量人血浆中万古霉素的浓度。流动相为缓冲液(50 mM磷酸二氢铵,pH 2.4)和乙腈的混合物,体积比为88 : 12。在C18柱(125×4.6 mm,粒径5 µm)上进行分离,室温下等度流速为0.370 mL/min,在215 nm处进行紫外检测。按照欧洲药品管理局(EMA)指南,对该方法在人血浆中万古霉素的灵敏度、准确性、精密度以及稳定性进行了验证。通过定量65份人血浆样本在给予治疗相关剂量后万古霉素的谷浓度,进行了万古霉素的治疗药物监测。
所开发的方法灵敏度足以定量人血浆中低至0.25 mg/L的万古霉素浓度。此外,该方法在定量万古霉素未知浓度方面被证明准确且精密。短期、长期和冻融稳定性评估证明了万古霉素在人血浆中的稳定性。使用该方法进行万古霉素的TDM表明,39份(60%)样本在目标谷浓度范围(TTCR)内,即10 - 20 mg/L,而23份样本(35.4%)低于TTCR,3份样本(4.6%)高于此范围。
所开发的方法对于定量人血浆中万古霉素灵敏且经济高效。样本分析结果表明,所开发的方法可可靠地用于万古霉素的TDM。